227 related articles for article (PubMed ID: 19086848)
1. Fhit tumor suppressor: guardian of the preneoplastic genome.
Pichiorri F; Palumbo T; Suh SS; Okamura H; Trapasso F; Ishii H; Huebner K; Croce CM
Future Oncol; 2008 Dec; 4(6):815-24. PubMed ID: 19086848
[TBL] [Abstract][Full Text] [Related]
2. A Fhit-ing role in the DNA damage checkpoint response.
Ishii H; Wang Y; Huebner K
Cell Cycle; 2007 May; 6(9):1044-8. PubMed ID: 17457056
[TBL] [Abstract][Full Text] [Related]
3. Fragile gene product, Fhit, in oxidative and replicative stress responses.
Okumura H; Ishii H; Pichiorri F; Croce CM; Mori M; Huebner K
Cancer Sci; 2009 Jul; 100(7):1145-50. PubMed ID: 19486340
[TBL] [Abstract][Full Text] [Related]
4. Initiation of genome instability and preneoplastic processes through loss of Fhit expression.
Saldivar JC; Miuma S; Bene J; Hosseini SA; Shibata H; Sun J; Wheeler LJ; Mathews CK; Huebner K
PLoS Genet; 2012; 8(11):e1003077. PubMed ID: 23209436
[TBL] [Abstract][Full Text] [Related]
5. [FHIT--tumor suppressor protein involved in induction of apoptosis and cell cycle regulation].
Pecherzewska R; Nawrot B
Postepy Biochem; 2009; 55(1):66-75. PubMed ID: 19514467
[TBL] [Abstract][Full Text] [Related]
6. Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant.
Ottey M; Han SY; Druck T; Barnoski BL; McCorkell KA; Croce CM; Raventos-Suarez C; Fairchild CR; Wang Y; Huebner K
Br J Cancer; 2004 Nov; 91(9):1669-77. PubMed ID: 15494723
[TBL] [Abstract][Full Text] [Related]
7. FHIT as tumor suppressor: mechanisms and therapeutic opportunities.
Pekarsky Y; Palamarchuk A; Huebner K; Croce CM
Cancer Biol Ther; 2002; 1(3):232-6. PubMed ID: 12432269
[TBL] [Abstract][Full Text] [Related]
8. Fhit modulates the DNA damage checkpoint response.
Ishii H; Mimori K; Inoue H; Inageta T; Ishikawa K; Semba S; Druck T; Trapasso F; Tani K; Vecchione A; Croce CM; Mori M; Huebner K
Cancer Res; 2006 Dec; 66(23):11287-92. PubMed ID: 17145874
[TBL] [Abstract][Full Text] [Related]
9. The role of deletions at the FRA3B/FHIT locus in carcinogenesis.
Huebner K; Druck T; Siprashvili Z; Croce CM; Kovatich A; McCue PA
Recent Results Cancer Res; 1998; 154():200-15. PubMed ID: 10027001
[TBL] [Abstract][Full Text] [Related]
10. Fhit-Fdxr interaction in the mitochondria: modulation of reactive oxygen species generation and apoptosis in cancer cells.
Druck T; Cheung DG; Park D; Trapasso F; Pichiorri F; Gaspari M; Palumbo T; Aqeilan RI; Gaudio E; Okumura H; Iuliano R; Raso C; Green K; Huebner K; Croce CM
Cell Death Dis; 2019 Feb; 10(3):147. PubMed ID: 30770797
[TBL] [Abstract][Full Text] [Related]
11. Fhit loss-associated initiation and progression of neoplasia in vitro.
Karras JR; Schrock MS; Batar B; Zhang J; La Perle K; Druck T; Huebner K
Cancer Sci; 2016 Nov; 107(11):1590-1598. PubMed ID: 27513973
[TBL] [Abstract][Full Text] [Related]
12. The FHIT gene product: tumor suppressor and genome "caretaker".
Waters CE; Saldivar JC; Hosseini SA; Huebner K
Cell Mol Life Sci; 2014 Dec; 71(23):4577-87. PubMed ID: 25283145
[TBL] [Abstract][Full Text] [Related]
13. Correlation of fragile histidine triad (Fhit) protein structural features with effector interactions and biological functions.
Pichiorri F; Okumura H; Nakamura T; Garrison PN; Gasparini P; Suh SS; Druck T; McCorkell KA; Barnes LD; Croce CM; Huebner K
J Biol Chem; 2009 Jan; 284(2):1040-9. PubMed ID: 19004824
[TBL] [Abstract][Full Text] [Related]
14. Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FHIT and WWOX at chromosome fragile sites.
Ishii H; Mimori K; Inageta T; Murakumo Y; Vecchione A; Mori M; Furukawa Y
Mol Cancer Res; 2005 Mar; 3(3):130-8. PubMed ID: 15798093
[TBL] [Abstract][Full Text] [Related]
15. Fhit and Wwox loss-associated genome instability: A genome caretaker one-two punch.
Schrock MS; Karras JR; Guggenbiller MJ; Druck T; Batar B; Huebner K
Adv Biol Regul; 2017 Jan; 63():167-176. PubMed ID: 27773744
[TBL] [Abstract][Full Text] [Related]
16. Nit1 and Fhit tumor suppressor activities are additive.
Sun J; Okumura H; Yearsley M; Frankel W; Fong LY; Druck T; Huebner K
J Cell Biochem; 2009 Aug; 107(6):1097-106. PubMed ID: 19479888
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms shaping the mutational landscape of the FRA3B/FHIT-deficient cancer genome.
Saldivar JC; Park D
Genes Chromosomes Cancer; 2019 May; 58(5):317-323. PubMed ID: 30242938
[TBL] [Abstract][Full Text] [Related]
18. Fragile site orthologs FHIT/FRA3B and Fhit/Fra14A2: evolutionarily conserved but highly recombinogenic.
Matsuyama A; Shiraishi T; Trapasso F; Kuroki T; Alder H; Mori M; Huebner K; Croce CM
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):14988-93. PubMed ID: 14630947
[TBL] [Abstract][Full Text] [Related]
19. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
20. Fhit deficiency-induced global genome instability promotes mutation and clonal expansion.
Miuma S; Saldivar JC; Karras JR; Waters CE; Paisie CA; Wang Y; Jin V; Sun J; Druck T; Zhang J; Huebner K
PLoS One; 2013; 8(11):e80730. PubMed ID: 24244712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
